NNC 01-0687 explained

Class:	Dopamine D1-like receptor antagonist
Cas Number:	128022-68-4
Pubchem:	164252
Drugbank:	DB05419
Chemspiderid:	144027
Unii:	K389NU4SEV
Synonyms:	ADX-10061; CEE 03-310; CEE-310; NNC 01-687; NNC-687; NO-687
Iupac Name:	(5S)-5-(2,3-dihydro-1-benzofuran-7-yl)-3-methyl-8-nitro-1,2,4,5-tetrahydro-3-benzazepin-7-ol
C:	19
H:	20
N:	2
O:	4
Smiles:	CN1CCC2=CC(=C(C=C2[C@H](C1)C3=CC=CC4=C3OCC4)O)[N+](=O)[O-]
Stdinchi:	1S/C19H20N2O4/c1-20-7-5-13-9-17(21(23)24)18(22)10-15(13)16(11-20)14-4-2-3-12-6-8-25-19(12)14/h2-4,9-10,16,22H,5-8,11H2,1H3/t16-/m1/s1
Stdinchikey:	XZPSYCOYKJRHKE-MRXNPFEDSA-N

NNC 01-0687 (also known as ADX-10061, CEE-03-310, or NNC-687) is a selective dopamine D₁-like receptor antagonist of the benzazepine group which was under development as an experimental antipsychotic for the treatment of schizophrenia but was never marketed.^{[1] [2] [3]} Its development for schizophrenia was discontinued due to lack of effectiveness in clinical trials.^[4]

Subsequently, NNC 01-0687 was developed under the code name ADX-10061 for treatment of substance dependence and was studied for smoking cessation, alcohol dependence, and cocaine dependence. It was also developed for treatment of sleep disorders. However, development for all of these indications was also discontinued, by 2007, and the drug was never marketed for any use.

NNC 01-0687 was first described in the scientific literature by 1992.^[5]

See also

• Berupipam (NNC 22-0010)
• Ecopipam (SCH-39166)
• Odapipam (NNC 01-0756)
• SCH-23390

Notes and References

1. Web site: ADX 10061 . AdisInsight . Springer Nature Switzerland AG . 3 October 2007 . 19 October 2024.
2. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA . Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents . Molecular Psychiatry . 17 . 12 . 1206–1227 . December 2012 . 22584864 . 10.1038/mp.2012.47 .
3. Heidbreder C . Recent Advances in the Pharmacotherapeutic Management of Drug Dependence and Addiction . Current Psychiatry Reviews . Bentham Science Publishers Ltd. . 1 . 1 . 1 January 2005 . 1573-4005 . 10.2174/1573400052953538 . 45–67.
4. Bolós J . Current strategies for the development of novel antipsychotic drugs . Mini Reviews in Medicinal Chemistry . 3 . 3 . 239–251 . May 2003 . 12570839 . 10.2174/1389557033488169 .
5. Christensen JV . Determination of (+)-5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5- tetrahydro-1H-3-benzazepin-7-ol (NNC 01-0687), a novel dopamine D-1 receptor antagonist, in plasma by solid-phase extraction and high-performance liquid chromatography . Journal of Chromatography . 577 . 2 . 366–370 . June 1992 . 1301070 . 10.1016/0378-4347(92)80261-n .